Literature DB >> 3664533

IgM response and resistance to ascites tumor growth.

J L Subiza1, J Coll, R Alvarez, M Valdivieso, E G de la Concha.   

Abstract

Antibody response and protection against Ehrlich ascites tumor (EAT) was studied in eight EAT-immunized strains of mice (AL/N, BALB/C, C57BL/6J, F1 (C57BL/6 x BALB/C), C57BL/10J, B10.BR, CBA/Ca, SW). The results showed a close association between IgM response and resistance to subsequent tumor challenge. Thus, protection was only achieved in those animals giving a measurable IgM response against EAT cell surface antigens, i.e., all inbred strains of mice tested, except CBA/Ca, and some outbred SW mice. The lack of IgM response to these antigens in CBA/Ca was not linked to the strain H-2 haplotype. Resistance could be passively transferred to nonimmunized mice by means of serum, or purified IgM, from protected immune animals. Moreover, complement depletion by cobra venom factor treatment did not modify the protection afforded to those mice. IgM reactivity to EAT cells was completely abolished by previous cell trypsinization. Trypsin removed but did not destroy the antigen(s) recognized by the IgM, since all its activity could be absorbed with the supernatant of the EAT cell trypsinization. Absorption assays with this supernatant treated with different agents, showed that lipids, simple peptides and nucleic acids were not important components of the antigenic determinants. On the contrary, its susceptibility to beta-galactosidase and particularly to a mild periodate oxidation, suggested that determinants recognized by the IgM against the EAT cell surface are carbohydrate in nature.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3664533     DOI: 10.1007/bf00199946

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Protection of mice from malignant tumor implants by enucleated tumor cells.

Authors:  K K Sethi; H Brandis
Journal:  J Natl Cancer Inst       Date:  1974-10       Impact factor: 13.506

2.  Evidence against the presence of H2 histocompatibility antigens in Ehrlich ascites tumour cells.

Authors:  L Chen; J F Watkins
Journal:  Nature       Date:  1970-02-21       Impact factor: 49.962

3.  Theoretical considerations of the role of antigen structure in B cell activation.

Authors:  A S Perelson; F W Wiegel
Journal:  Fed Proc       Date:  1981-04

4.  Cell-mediated lysis of tumor targets directed by murine monoclonal antibodies of IgM and all IgG isotypes.

Authors:  P Ralph; I Nakoinz
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

Review 5.  Tumor-associated carbohydrate antigens.

Authors:  S Hakomori
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

6.  Immune mechanisms in Ehrlich ascites tumor growth in mice.

Authors:  M Marusić
Journal:  Eur J Cancer       Date:  1979-01       Impact factor: 9.162

7.  Ehrlich ascites tumor cell surface labeling and kinetics of glycocalyx release.

Authors:  T C Smith; C Levinson
Journal:  J Supramol Struct       Date:  1979

8.  A naturally occurring complement dependent human IgM macroglobulin inhibitory to Ehrlich ascites tumor cells.

Authors:  M M Goff; S A Armentrout
Journal:  J Clin Lab Immunol       Date:  1982-12

9.  Resistance to Ehrlich ascites tumor in a strain of dystrophic mice.

Authors:  P J Carry; D M Prescott; G K Ogilvie
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

10.  A monoclonal IgM lambda macroglobulin with specificity for lacto-N-tetraose in a patient with bronchogenic carcinoma.

Authors:  E A Kabat; J Liao; J Shyong; E F Osserman
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

View more
  1 in total

1.  Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells.

Authors:  Andrey S Dobroff; Elaine G Rodrigues; Maria A Juliano; Dayson M Friaça; Ernesto S Nakayasu; Igor C Almeida; Renato A Mortara; Jacqueline F Jacysyn; Gustavo P Amarante-Mendes; Walter Magliani; Stefania Conti; Luciano Polonelli; Luiz R Travassos
Journal:  Transl Oncol       Date:  2010-08-01       Impact factor: 4.243

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.